THERAVANCE INITIATES PHASE I STUDY WITH INVESTIGATIONAL MEDICINE FOR GASTROINTESTINAL MOTILITY DYSFUNCTION

Theravance has enrolled the first subjects in a Phase I clinical study designed to assess the safety, tolerability and pharmacokinetics of its investigational gastrointestinal (GI) prokinetic, TD-2749.

TD-2749 is a selective 5-HT4 agonist discovered by Theravance through the application of multivalent drug design in a drug discovery program dedicated to finding new medicines for GI motility disorders such as chronic constipation, constipation-predominant irritable bowel syndrome, opioid-induced constipation, functional dyspepsia and diabetic gastroparesis.